Pallas Health vs Mochi Health: Clinician Model and Pricing Compared
Pallas Health vs Mochi Health answers which telehealth weight-loss approach fits you: Pallas pairs a US-licensed clinician with either FDA-approved brand pens or US-compounded GLP-1 options, while Mochi centers on live video visits, membership pricing, and nationwide access. Early verdict: choose Pallas if you want a single intake that can produce either brand-name or compounded medication with provider care included; choose Mochi if you prioritize a live 5-minute video visit and membership-plus-medication pricing that can start as low as $99.
Start Pallas intake for clinician-personalized options
How the two models differ at a glance
Both services offer access to GLP-1 medications, including compounded semaglutide and tirzepatide, but they differ in clinical workflow, pricing structure, and membership requirements. Below are the most distinctive supported differences: clinical visit style and speed, pricing format and transparency, availability of brand-name options, membership or plan inclusions, and compounding regulatory notes.
Clinical visit style and patient interaction
Pallas operates with a US-licensed clinician reviewing your intake and personalizing treatment, mostly asynchronously: 100% online and asynchronous in most states, with a video visit required in seven states plus Washington D.C. Mochi emphasizes synchronous care: live video visits with a doctor bookable in about 5 minutes and ongoing appointment availability plus 24/7 support. If real-time conversation matters, Mochi provides a live physician consult; if asynchronous intake is acceptable, Pallas completes much care without a video visit in most states.
Pricing structure and transparency
Pallas markets an all-in plan price that includes provider care, check-ins and messaging with no membership fee. Compounded semaglutide is listed as $139 first month, then $597 every 12 weeks, a $199/month average; compounded tirzepatide is $179 first month then $897 every 12 weeks, a $299/month average. Pallas also offers cash-pay brand-name pens with published monthly figures. Mochi uses a membership-plus-medication model where pricing starts from $99/month and offers 50% off your first month with code BESTWLHALFOFF; total ongoing cost varies by plan and medication and is therefore less transparent than flat-rate competitors.
See Pallas pricing and plan inclusions
Brand-name options versus compounded focus
Pallas explicitly offers FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro as options alongside clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. Mochi emphasizes compounded medication offerings with lower starting prices and also lists a broader catalog of compounded oral and injectable options. If access to brand-name pens is a priority, Pallas supports that pathway; if you want lower starting costs on compounded products and a membership model, Mochi highlights that approach.
Membership, support hours, and service inclusions
Pallas bills itself as no membership fee: provider care is included in plan price and features a self-serve portal, provider messaging, and a free companion app. Care-team hours are weekdays 9 AM to 5 PM ET and no emergency services are offered. Mochi operates with ongoing appointment availability and 24/7 support as part of its membership model, which may suit people who need more flexible scheduling or round-the-clock access. Mochi also notes that some promotional rates apply only to initial months.
Regulatory and quality notes shared by both
Both providers include the regulatory qualifier that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas adds that its compounded medications are prepared by US-licensed compounding pharmacies and that the medication you receive may differ in appearance from images. Mochi also highlights that compounded offerings are prescribed at provider discretion and that individual results are not guaranteed.
| Criteria | Pallas Health | Mochi Health |
|---|---|---|
| Clinical visit model | Asynchronous intake; clinician review; video required in some states | Live video visits with a doctor bookable in about 5 minutes |
| Price presentation | All-in plan pricing; compounded semaglutide $139 first month then $199/mo avg | Membership plus medication; pricing from $99/month and 50% off first month |
| Brand-name availability | FDA-approved Wegovy, Ozempic, Zepbound, Mounjaro available | Compounded focus; branded options not primary offering |
| Support and availability | Care-team weekdays 9 AM to 5 PM ET; 100% online | 24/7 support and ongoing appointments |
| Compounding regulatory note | Compounded meds are not FDA-approved; prepared by US compounding pharmacies | Compounded meds are not FDA-approved; prescribed at provider discretion |
Compare Pallas plans and start intake
Final comparison and how to choose
Both Pallas Health and Mochi Health give telehealth access to GLP-1 treatments and include the shared regulatory caution that compounded medications are not FDA-approved. The choice rests on workflow and pricing: Pallas provides a clinician-led decision between brand-name pens and US-compounded options inside an all-in plan price with no membership fee and specific published compounded plan figures; Mochi delivers synchronous live video visits in about 5 minutes, 24/7 support, and a membership-plus-medication model with promotional first-month discounts and starting pricing from $99.
Choose Pallas if you want a single intake that can yield either FDA-approved brand pens or clinician-personalized US-compounded medication inside an all-in plan price that includes provider care. Choose Mochi if you want live, bookable video visits with a doctor within minutes, ongoing 24/7 support, and membership pricing that can begin as low as $99 with an initial promotional discount.